Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan needs REMS, source data documentation for Botox approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Allergan receives a "complete response" letter from FDA for its Botox (botulinum toxin type A) sBLA for upper limb spasticity in post-stroke adults that identifies three items that Allergan must complete before the agency signs off on the new use. One of the items is a Risk Evaluation and Mitigation Strategy that FDA has put in place for all botulinum toxin products for all uses; Allergan's program should mimic the one that accompanied the approval of Ipsen/Medicis' Dysport. Allergan has already submitted a REMS, but the agency has not yet reviewed it. FDA also wants a safety update from clinical and non-clinical studies across all Botox indications. Further, the agency asked the company to independently verify underlying patient source documentation at study sites relating to one of the pivotal trials conducted in 1999, and provide an updated analysis; the firm estimates this will take 60 to 90 days. The final item in the action letter, regarding revisions to proposed labeling, contains a boon for Allergan. FDA "noted the focal nature of Botox treatments and the similarities of spasticity across conditions, and thus proposed revised labeling that would broaden the indication of use to upper limb spasticity regardless of cause," Allergan reports. The agency also requested a post-approval study in pediatric patients because of the frequency of upper limb spasticity in juvenile cerebral palsy patients. "Allergan hopes to discuss with the FDA a protocol that, if successful, would support an approval for the treatment of children suffering from spasticity," the firm adds

You may also be interested in...



Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel